NasdaqGS:PRAXBiotechs
Praxis Precision Medicines (PRAX) Is Down 5.4% After Major Institutional Buying and FDA Filings - Has The Bull Case Changed?
In recent months, Driehaus Capital Management and Deerfield Management Company have sharply increased their holdings in Praxis Precision Medicines, adding hundreds of thousands of shares and committing a combined investment of more than US$346.79 million as the company filed two FDA new drug applications for ulixacaltamide and relutrigine.
This combination of larger institutional ownership, advancing late‑stage neuroscience candidates and a cash position supported by roughly US$1.55 billion...